---
title: "EyeConic: Qualification for Cone-Optogenetics"
nct_id: NCT05294978
overall_status: RECRUITING
sponsor: Institute of Molecular and Clinical Ophthalmology Basel
study_type: OBSERVATIONAL
primary_condition: Retinal Dystrophies
countries: United States, China, Germany, Hungary, Italy, Switzerland, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05294978.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05294978"
ct_last_update_post_date: 2025-07-31
last_seen_at: "2026-05-12T07:33:51.984Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# EyeConic: Qualification for Cone-Optogenetics

**Official Title:** Qualification for Cone-Optogenetics (EyeConic)

**NCT ID:** [NCT05294978](https://clinicaltrials.gov/study/NCT05294978)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1000
- **Lead Sponsor:** Institute of Molecular and Clinical Ophthalmology Basel
- **Conditions:** Retinal Dystrophies
- **Start Date:** 2021-07-01
- **Completion Date:** 2026-12
- **CT.gov Last Update:** 2025-07-31

## Brief Summary

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

## Detailed Description

In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria (patients):

* Diagnosis of generalized IRD
* Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
* Availability of macular optical coherence tomography (OCT)

Inclusion Criteria (controls):

* Normal ophthalmic findings
* Availability of macular optical coherence tomography (OCT)

Exclusion Criteria (all):

* Other eye diseases with a significant effect on vision or retinal structure
* Extraocular disease affecting retinal structure such as neurodegenerative diseases
```

## Arms

- **Patients** — -Availability of macular optical coherence tomography (OCT)
- **Controls** — -Availability of macular optical coherence tomography (OCT)

## Interventions

- **Optical coherence tomography (OCT)** (DIAGNOSTIC_TEST) — Data of macular optical coherence tomography (OCT)

## Primary Outcomes

- **OCT - Central retinal volume** _(time frame: Baseline (about 10 minutes))_ — Number of participants with preserved central retinal volume

## Locations (9)

- University of California San Francisco, Department of Ophthalmology, San Francisco, California, United States — _RECRUITING_
- Bascom Palmer Eye Institute, Miami, Florida, United States — _RECRUITING_
- University of Pittsburgh, Department of Ophthalmology, Pittsburgh, Pennsylvania, United States — _RECRUITING_
- Beijing Institute of Ophthalmology, Beijing, China — _RECRUITING_
- Universitätsklinikum Tübingen Augenklinik, Tübingen, Germany — _RECRUITING_
- Semmelweis University, Department of Ophthalmology, Budapest, Hungary — _RECRUITING_
- Oculista Ospedale Parma, Parma, Italy — _RECRUITING_
- University Hospital Basel, Eye Clinic, Basel, Switzerland — _RECRUITING_
- Moorfields Eye Hospital, London, United Kingdom — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of california san francisco, department of ophthalmology|san francisco|california|united states` — added _(2026-05-12)_
- `locations.bascom palmer eye institute|miami|florida|united states` — added _(2026-05-12)_
- `locations.university of pittsburgh, department of ophthalmology|pittsburgh|pennsylvania|united states` — added _(2026-05-12)_
- `locations.beijing institute of ophthalmology|beijing||china` — added _(2026-05-12)_
- `locations.universitätsklinikum tübingen augenklinik|tübingen||germany` — added _(2026-05-12)_
- `locations.semmelweis university, department of ophthalmology|budapest||hungary` — added _(2026-05-12)_
- `locations.oculista ospedale parma|parma||italy` — added _(2026-05-12)_
- `locations.university hospital basel, eye clinic|basel||switzerland` — added _(2026-05-12)_
- `locations.moorfields eye hospital|london||united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05294978.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05294978*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*